Now Playing
Opinion|Videos|October 30, 2026
Immunology of gMG + CD19 Rationale
Author(s)Suraj Muley, MD, FAAN, FRCP, FACP
Dr. Muley outlines the immunopathogenesis of generalized myasthenia gravis, tracing the cascade from thymic dysregulation through autoreactive T cells, B cell activation, and plasmablast/plasma cell formation to autoantibody production against AChR and MuSK.
Advertisement
Episodes in this series
Dr. Muley outlines the immunopathogenesis of generalized myasthenia gravis, tracing the cascade from thymic dysregulation through autoreactive T cells, B cell activation, and plasmablast/plasma cell formation to autoantibody production against AChR and MuSK. He explains how existing therapies (complement inhibitors, FcRn blockers) target downstream mechanisms, while inebilizumab -- a CD19-directed antibody -- works upstream by depleting the B cell populations responsible for autoantibody production.
Advertisement
Related to this article
Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.
Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.
The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.
Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines
2
World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number
3
Investigating the Genetic Link Between EBV and MS Risk: David A. Hafler, MD, FANA; Yoshiaki Yasumizu, MD, PhD
4
World Stroke Day: Preventing Perioperative Stroke With Predictive Tools
5